ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: House Cuts NCI Rescission To $7.73 Million; Weinhuse, Ultmann New ACCR, ASCO Presidents

May 8, 1981

Program Project Payline Is 125; Budget Cuts Will Allow NCI To Fund 49 Competing P01s

February 28, 1992

FDA Approves Generic Oncology Injectable Currently In Shortage

September 27, 2013

Von Eschenbach Takes NCI’s Helm As Bush Proposes Budget Increase.

February 8, 2002

In Brief: Robert Weinberg to Receive Bristol-Myers Award; Leffall Chosen for Poster Series

April 13, 1984

CCRAC Shoots Down Two Projects, Approves Others

December 15, 1978